CliffBio
biologic

Breyanzi

lisocabtagene maraleucel

Loss of exclusivityFebruary 2033projected — 12-year biologic exclusivity estimate
CompanyJuno Therapeutics, Inc. a Bristol Myer-Squibb Company

Drug detail

Brand nameBreyanzi
Active ingredientlisocabtagene maraleucel
Strength4.6ML/VIAL
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Breyanzi patent cliff — loss of exclusivity February 2033 | CliffBio